Corcept Therapeutics Faces Setback in Korlym Patent Dispute with Teva

Corcept Therapeutics' stock declined after an appeals court ruled in favor of Teva Pharmaceuticals in a patent dispute concerning Corcept's drug Korlym.

19 Feb, 16:10 — 19 Feb, 16:10